Pertussis vaccination during pregnancy: Antibody persistence in infants

Vaccine

Volumn 34, Issue 33, 2016, Pages 3719-3722

  Vilajeliu, Alba ^a   Ferrer, Laia ^a   Munrós, Jordina ^a   Goncé, Anna ^a   López, Marta ^a   Costa, Josep ^a   Bayas, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antibody persistence; Infant vaccination; Maternal vaccination; Neonatal pertussis

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; MATERNAL ANTIBODY;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GESTATION PERIOD; HALF LIFE TIME; HUMAN; INFANCY; INFANT; MALE; MATERNAL TREATMENT; OBSERVATIONAL STUDY; OBSTETRIC DELIVERY; PERINATAL PERIOD; PERTUSSIS; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; VACCINATION; YOUNG ADULT; BLOOD; PASSIVE IMMUNIZATION; WHOOPING COUGH;

ADULT; ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HALF-LIFE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; INFANT; MALE; PREGNANCY; PROSPECTIVE STUDIES; WHOOPING COUGH; YOUNG ADULT;

EID: 84991011484     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.05.051     Document Type: Article

References (20)

1. [1] Souder, E., Long, S.S., Pertussis in the era of new strains of Bordetella pertussis. Infect Dis Clin North Am 29 (2015), 699–713.
2. [2] Van Hoek, A.J., Campbell, H., Amirthalingam, G., Andrews, N., Miller, E., The number of deaths among infants under one year of age in England with pertussis: results of a capture/recapture analysis for the period 2001 to 2011. Eurosurveillance, 2013, 2001, 18.
3. [3] Grupo de Trabajo tos ferina 2015 de la Ponencia de Programa y Registro de Vacunaciones. Adenda al programa de vacunación frente a tos ferina en España: vacunación en el embarazo; 2015 < http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Adenda_TosFerinaEmbarazo.pdf>.
4. [4] Sawyer, M., Liang, J.L., Messonnier, N., Clark, T.A., Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – advisory committee on immunization practices (ACIP), 2012. Morb Mortal Wkly Rep 62 (2013), 131–135.
5. [5] Vilajeliu, A., Goncé, A., López, M., Costa, J., Rocamora, L., Ríos, J., et al. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn. Vaccine 33 (2015), 1056–1062.
6. [6] Healy, C.M., Rench, M.A., Baker, C.J., Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 56 (2013), 539–544.
7. [7] Munoz, F.M., Bond, N.H., Maccato, M., Pinell, P., Hammill, H.A., Swamy, G.K., et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants. JAMA 311 (2014), 1760–1769.
8. [8] Wiley, K.E., Zuo, Y., Macartney, K.K., McIntyre, P.B., Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine 31 (2013), 618–625.
9. [9] Heininger, U., Riffelmann, M., Bär, G., Rudin, C., von König, C.-H.W., The protective role of maternally derived antibodies against bordetella pertussis in young infants. Pediatr Infect Dis J 32 (2013), 695–698.
10. [10] Dabrera, G., Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and wales, 2012–2013. Clin Infect Dis 60 (2015), 333–337.
11. [11] Vilajeliu, A., Urbiztondo, L., Martínez, M., Batalla, J., Cabezas, C., Vacunació de les dones embarassades contra la tos ferina a Catalunya. , 2014.
12. [12] Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica Triaxis n.d. < http://www.aemps.gob.es/cima/pdfs/es/ft/71870/FT_71870.pdf>.
13. [13] Xing D, Newland P, Riffelmann M, Meade B, Corbel M. International collaborative study: evaluation of proposed international standard for pertussis antiserum (human). Geneva; 2008.
14. [14] Lynn, F., Reed, G.F., Meade, B.D., Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 3 (1996), 689–700.
15. [15] Meade, B., Deforest, A., Edwards, K., Romani, T., Lynn, F., O'Brien, C., et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96 (1995), 570–575.
16. [16] Taranger, J., Trollfors, B., Lagergård, T., Sundh, V., Bryla, D.A., Schneerson, R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 (2000), 1010–1013.
17. [17] Abu Raya, B., Srugo, I., Kessel, A., Peterman, M., Bader, D., Gonen, R., et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels – a prospective study. Vaccine 32 (2014), 5787–5793.
18. [18] Maertens, K., Nadège, R., Huygen, K., Hens, N., Van, Damme P, Leuridan, E., Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine 34 (2016), 142–150.
19. [19] Eberhardt, C.S., Blanchard-Rohner, G., Lemaître, B., Boukrid, M., Combescure, C., Othenin-Girard, V., et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 62 (2016), 829–836.
20. [20] Keller-Stanislawski, B., Englund, J.a., Kang, G., Mangtani, P., Neuzil, K., Nohynek, H., et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 32 (2014), 7057–7064.